Differences of D1-like mRNA levels in the NCL (A) and the anterior forebrain (aFB; B) between the trained groups. by Christina Herold (323010)

“…<p>In the NCL and in the aFB, D1A receptor expression levels decreased in the S-R and in the SMTS groups, and increased to control levels after training in the DMTS group. …”

Comparison of intestinal and complete nasal turbinate microbiota between mock- and sequentially-infected mice. by Yuhao Li (1559569)

Pbp1 promotes the translation of Puf3-target mRNAs in respiratory conditions. by Floortje van de Poll (15810877)

Y-P30 effects on expression of synaptic proteins. by Janine R. Neumann (6330863)

“…Mean ± SEM of four (A) and three (B) independent experiments normalized to the expression of glucose-6-phosphate dehydrogenase (G6PDH) or 18S rRNA. …”

Calcium levels in PC12 cells exposed to SMF, the A_2AR agonist CGS21680 or antagonist ZM241385. by Zhiyun Wang (360002)

“…(<b>B</b>) In a separate experiment cells were evaluated at the three hour time point when the largest difference between SMF-treated and untreated cells occurred but before cell integrity was compromised from the assay conditions (e.g., from using Ca²⁺ and Mg²⁺ free D-PBS). …”

Total inhibitory input as a function of figure size. by Hans Supèr (285410)

“…<p><b>A</b>: The total amount of inhibitory input that a neuron receives increases for larger figures for neurons located on the figure. …”

Control analysis for the specificity of PFI effect on CSF flow - No correlation between the d/dt gGM and the CSF amplitude. by Juliana Zimmermann (10507091)

Luciferase reporter virus characterisation in vivo. by Michael P. Nicoll (3175491)

A representative case of epiretinal membrane (ERM) in a glaucomatous eye which showed worsening of the central visual field after vitrectomy. by Shunsuke Tsuchiya (4033583)

“…The optical coherence tomography (OCT) image shows an ERM. (B) A visual field test at the first postoperative session (7 months after surgery) revealed decreased sensitivity especially in the central area. …”

Effect of MMP9 on phFAK and ILK expression. by Nabila Djaziri (17537499)

“…Note that the ratio is significantly decreased upon MMP9 deficiency. Values are mean ± SEM, ***p = 0.0016. …”

Fold change with steady state myocardial mRNA levels for components of the inflammasome. by Stephanie L. Samani (17896610)

Fig 1 - by Stephanie L. Samani (17896610)

Mortality of <i>C. maculatus</i> after 24h exposure to GO and GO-GA NPs. by Huda H. Elbehery (22492996)

Inferring the structure of internal beliefs about a task. by Richard D. Lange (11768146)

“…<p><b>a)</b> Trial-to-trial fluctuations in the posterior beliefs about <b>x</b> imply trial-to-trial variability in the mean responses representing that posterior. …”

Histogram and scatterplot of rare nsSNPs of PTB-related gene mutations in comparison with functional impact analyses. by Muhammad Bilal Azmi (14519913)

Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”